Cargando…
Elevated Platelet Count is Associated with Poor Survival After Transarterial Chemoembolization Treatment in Patients with Hepatocellular Carcinoma: A Cohort Study
BACKGROUND: Platelet count (PLT) has been proved as an essential biomarker for the survival of hepatocellular carcinoma (HCC). However, the prognostic value of PLT change (ΔPLT) is still uncertain. The aim of this study was to explore the relationship between ΔPLT and HCC survival after transarteria...
Autores principales: | Lu, linbin, Zhang, Yan, Zheng, Peichan, Wu, Zhixian, Wang, Xuewen, Chen, Yaying, Chen, Xiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573485/ https://www.ncbi.nlm.nih.gov/pubmed/33117753 http://dx.doi.org/10.2147/JHC.S274349 |
Ejemplares similares
-
Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study
por: Lu, Linbin, et al.
Publicado: (2021) -
Association between platelet count and hepatocellular carcinoma overall survival: a large retrospective cohort study
por: Lu, Linbin, et al.
Publicado: (2020) -
Prognosis of Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization(MC-hccAI 001): Development and Validation of the ALFP Score
por: Gong, Baocuo, et al.
Publicado: (2023) -
Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study
por: Lu, Linbin, et al.
Publicado: (2022) -
The aMAP Score is an Independent Risk Factor for Intermediate-stage Hepatocellular Carcinoma: A Large Retrospective Cohort Study
por: Chen, Yaying, et al.
Publicado: (2023)